HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis Phase 2 trial tests whether adding fianlimab to cemiplimab works better than cemiplimab alone for people with advanced head and neck cancer that has come back or spread. About 120 participants whose tumors have a specific marker (PD-L1 positive) will receive either the drug …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody EPI-326 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cancer drug EXS74539 enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cocktail aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase II trial tests whether adding the targeted drug nimotuzumab to immunotherapy and chemotherapy before surgery can improve outcomes for people with locally advanced head and neck cancer. About 182 participants will receive the combination or standard treatment. The main …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Radiation reduction trial aims to boost quality of life for head and neck cancer survivors
Disease control Recruiting nowThis study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely avoid low-dose radiation to the neck afterward. The goal is to maintain cancer control while reducing side effects and improving quality …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Experimental combo aims to tackle returning head and neck cancer
Disease control Recruiting nowThis early-stage trial is testing whether giving a drug called chidamide along with a second round of radiation is safe for people whose head and neck cancer has returned after previous radiation. Only 6 participants will be enrolled to find the best dose and check for side effec…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests whether giving two drugs—ficerafusp alfa and pembrolizumab (Keytruda)—before surgery can shrink tumors in people with advanced head and neck cancer. About 32 participants with resectable, PD-L1-positive squamous cell carcinoma will receive the combination…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental combo aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis early-phase trial is testing whether a new drug called GV20-0251, combined with the immunotherapy sintilimab, is safe and can shrink tumors before surgery in people with head and neck cancer. Nine adults with advanced but removable tumors will receive two cycles of the drug …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug STRO-004 takes on advanced cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can a sixth day of radiation beat cancer recurrence?
Disease control Recruiting nowThis study compares two radiotherapy schedules for people with head and neck cancer who begin radiation more than 6 weeks after surgery. One group gets standard treatment (5 days a week), the other gets an accelerated schedule (6 days a week). The goal is to see if the faster sch…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New cancer drug MT-4561 enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo aims to control advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: LG Chem • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New scan spots hidden cancer spread before surgery
Diagnosis Recruiting nowThis Phase 2 trial tests whether a special PET/CT scan using [68Ga]Ga-FAPI-46 can detect early lymph node metastases in people with head and neck squamous cell carcinoma. The scan targets cancer-associated fibroblasts, which help create a welcoming environment for cancer to sprea…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: John O. Prior • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
App-Based symptom tracking may prevent dangerous weight loss in cancer patients
Symptom relief Recruiting nowThis study tests whether using a smartphone app to regularly report symptoms can help doctors catch problems early and reduce severe weight loss in head and neck cancer patients undergoing curative radiation or chemoradiation. About 192 adults will be enrolled. The goal is to see…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC